Everything tagged "insiders" across research, earnings, and macro.
12 articles
The market is obsessing over Gloo's fresh share sale and missing the more important signal: management is still guiding to EBITDA breakeven in Q3 and profitability in Q4 while insiders have lined up at least $6.0 million for the deal. At 0.50x sales after a 47.1% YTD collapse, this looks more like a stressed setup around dilution than a broken operating story.
Netskope’s story is not broken just because ARR growth has cooled. The market is obsessing over the post-IPO reset while management is still expanding distribution and embedding the platform into the enterprise AI stack.
Vicor’s selloff looks like an insider-optics panic, not a collapse in the AI power thesis. The business is still putting up beats, strong margins, and a raised Q2 outlook that says demand is alive.
Polestar did not lose its entire business when the U.S. connected-vehicle ruling hit, but it did lose the clean EV-turnaround narrative. PSNY now looks like a Europe-first restructuring story backed by insider buying, fresh capital support, and a market that still has to decide whether survival is enough.
Nuvectis took a painful dilution hit, but this is one of the rare biotech raises that actually improves the story. A $100 million financing landed right after a pipeline expansion deal, turning NVCT from a cash-tight single-asset bet into a funded three-program clinical setup.
Wallbox still looks ugly on the income statement, but the balance-sheet story changed more than the market seems willing to admit. A court-approved restructuring and $7.5 million of insider buying make WBX look less like a survival trade and more like an early recap turnaround.
CarMax looks like a turnaround stock, not a broken retailer, and the recent insider buying makes that distinction matter. Management is putting real money behind a post-earnings repair story just as revenue, unit trends, and cost discipline start to move the right way.
Liberty Latin America looks more interesting now because the insider alignment around its preferred-stock rollout is unusually large and unusually timely. With Q1 operations running ahead of internal expectations and the stock still trading at just 0.48x sales, we think the market is still behind the turn.
Crane NXT’s post-earnings drop looks more like an overreaction than a broken thesis. Management kept 2026 EPS guidance intact, currency demand still looks solid, and the CEO just put about $1.01 million of personal money into CXT stock.
Mission Produce looks like a commodity produce stock on the surface, but the story changed fast. The Calavo acquisition, a new $100 million buyback, and heavy insider buying make AVO look more like a scale-and-capital-allocation setup than a pure avocado price trade.
American Battery just got a company-defining credibility boost with the full $115 million DOE grant reinstated. That does not erase execution risk, but it meaningfully changes the financing story at a moment when the business is also showing real revenue traction.
Comstock looks like a live execution setup, not just another speculative small cap, because insider buying is landing right on top of management's June commercial-operations target. The business is still messy on trailing numbers, but the combination of $3.15 million in insider buys, fresh financing, and a near-term startup catalyst keeps the bull case in control.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the Generator